The decree of the chief state sanitary doctor of the Russian Federation Anna Popova now provides for the use of the methods that determine the genetic material or antigen of the pathogen, and not only the PCR method, when testing for the detection of SARS-CoV-2. Shortly before the appearance of this document, scientists from The Gamaleya National Center of Epidemiology and Microbiology Research Center presented research results demonstrating that in some cases the value of antigenic tests may be higher than PCR. Learn more: https://vademec.ru/news/2021/03/31/rospotrebnadzor-priravnyal-antigennye-testy-na-covid-19-k-ptsr/
Roszdravnadzor has issued a temporary registration certificate for the first import test for SARS-Cov-2. The GeneFinder COVID-19 Plus RealAmp Kit diagnostic system manufactured by South Korean Osang Healthcare was brought to the market by Avivir LLC (part of the Himrar Group of Companies). At the end of April 2020, the tests received FDA authorization, and the American Emergency Management Agency purchased a batch of reagents from the company for $3 million.
The Russian company Avivir was the first to introduce two RBD tests to the domestic market for rapid diagnosis of the immune response to new coronavirus infection. The test systems presented by Avivir are designed for the qualitative detection of IgG class antibodies to the receptor-binding domain (RBD) of the SARS-CoV-2 S-protein. These screening tools from the South Korean manufacturer Sugentech and the Russian Rapid Bio determine the presence of virus-neutralizing anti-RBD antibodies in the blood.
Leave a request and we will advise you on the purchase of products